Effect of apolipoprotein C3 and apolipoprotein A1 polymorphisms on postprandial response to a fat overload in metabolic syndrome patients

Clinical Biochemistry

Volumn 43, Issue 16-17, 2010, Pages 1300-1304

  Clemente Postigo, M ^b   Queipo Ortuno M ^a   Valdivielso, P ^c   Tinahones, F J ^a,c   Cardona, F ^a,b  

^a Instituto de Salud Carlos III   (Spain)

^b Hospital University Carlos Haya de Málaga   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

APOA1; APOC3; Metabolic syndrome; Polymorphism; Postprandial hypertriglyceridemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; CHYLOMICRON; FAT; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; DIETARY FATS; FASTING; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTPRANDIAL PERIOD;

EID: 77957375411     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.08.014     Document Type: Article

References (42)

1. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 2007, 92:399-404.
2. Kawashiri M., Maugeais C., Rader D. High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. Curr. Atheroscler. Rep. 2000, 2:363-372.
3. Herbert P.N., Assmann G., Grotton J.A.M., Fredrickson D.S. Disorders of lipid and lipoprotein metabolism. Metabolic basis of inherited disease 1999, 589-651. McGraw-Hill, New York. J.B. Stanbury, D.S. Wyngaarden, D.S. Fredrickson, J.L. Goldstein, M.S. Brown (Eds.).
4. Wang Q.F., Liu X., O'Connell J., Peng Z., Krauss R.M., Rainwater D.L., VandeBerg J.L., Rubin E.M., Cheng J.F., Pennacchio L.A. Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons. Hum. Mol. Genet. 2004, 13:1049-1056.
5. Talmud P.J., Hawe E., Martin S., Olivier M., Miller G.J., Rubin E.M., Pennacchio L.A., Humphries S.E. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 2002, 11:3039-3046.
6. Shoulders C.C., Harry P.J., Lagrost L., White S.E., Shah N.F., North J.D., Gilligan M., Gambert P., Ball M.J. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis 1991, 87:239-247.
7. Onat A., Hergen G., Sansoy V., Fobker M., Ceyhan K., Toprak S., Assmann G. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003, 168:81-89.
8. Rees A., Stocks J., Sharpe C.R., Vella M.A., Shoulders C.C., Katz J., Jowett N.I., Baralle F.E., Galton D.J. Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia. J. Clin. Invest. 1985, 76:1090-1095.
9. Dammerman M., Sandkuijl L.A., Halaas J.L., Chung W., Breslow J.L. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. Proc. Natl Acad. Sci. USA 1993, 90:4562-4566.
10. Chhabra S., Narang R., Krishnan L.R., Vasisht S., Agarwal D.P., Srivastava L.M., Manchanda S.C., Das N. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genetic. 2002, 3:9-14.
11. Olivieri O., Bassi A., Stranieri C., Trabetti E., Martinelli N., Pizzolo F., Girelli D., Friso S., Pignatti P.F., Corrocher R. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J. Lipid Res. 2003, 44:2374-2381.
12. Pollin T.I., Damcott C.M., Shen H., Ott S.H., Shelton J., Horenstein R.B., Post W., McLenithan J.C., Bielak L.F., Peyser P.A., Mitchell B.D., Miller M., O'Connell J.R., Shuldiner A.R. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008, 322:1702-1705.
13. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 2001, 12:297-304.
14. van Dijk K.W., Rensen P.C., Voshol P.J., Havekes L.M. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?. Curr. Opin. Lipidol. 2004, 15:239-246.
15. Groenendijk M., Cantor R.M., de Bruin T.W., Dallinga-Thie G.M. The apoAI-CIII-AIV gene cluster. Atherosclerosis 2001, 157:1-11.
16. Ordovas J.M., Civeira F., Genest J., Craig S., Robbins A.H., Meade T., Pocovi M., Frossard P.M., Masharani U., Wilson P.W. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationship with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1991, 87:75-86.
17. Shoulders C.C., Grantham T.T., North J.D. Hypertriglyceridemia and apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Hum. Genet. 1996, 98:557-566.
18. Jr Gotto A.M., Pownall H.J., Havel R.J. Introduction to the plasma lipoproteins. Methods Enzymol. 1986, 128:3-41.
19. Barter P.J., Rye K.A. Molecular mechanisms of reverse cholesterol transport. Curr. Opin. Lipidol. 1996, 7:82-87.
20. Marin C., Lopez-Miranda J., Gomez P., Paz E., Perez-Martinez P., Fuentes F., Jimenez-Pereperez J.A., Ordovas J.M., Perez-Jimenez F. Effects of the human apolipoprotein A-I promoter G-A mutation on postprandial lipoprotein metabolism. Am. J. Clin. Nutr. 2002, 76:319-325.
21. Mata P., López-Miranda J., Pocovi M., Alonso R., Lahoz C., Marin C., Garces C., Cenarro A., Perez-Jimenez F., de Oya M., Ordovas J.M. Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis 1998, 137:367-376.
22. Lauer M.S., Fontanarosa P.B. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
23. Cardona F., Morcillo S., Gonzalo-Marín M., Garrido-Sanchez L., Macias-Gonzalez M., Tinahones F.J. Pro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome. Clin. Chem. 2006, 52:1920-1925.
24. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
25. Queipo-Ortuño M.I., Garcia-Ordoñez M.A., Colmenero J.D., Morata P. Hydrogen peroxide improves the efficiency of a peripheral blood PCR assay for diagnosis of human brucellosis. Biotechniques 1999, 27:248-250.
26. Jeenah M., Kessling A., Miller N., Humphries S.E. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol. Biol. Med. 1990, 7:233-241.
27. Lai C.Q., Parnell L.D., Ordovas J.M. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr. Opin. Lipidol. 2005, 16:153-166.
28. Morcillo S., Cardona F., Rojo-Martínez G., Almaraz M.C., Esteva I., Ruiz-De-Adana M.S., Olveira G., García-Fuentes E., Gómez-Zumaquero J.M., Soriguer F. Effect of the combination of the variants -75G/A APOA1 and Trp64Arg ADRB3 on the risk of type 2 diabetes (DM2). Clin. Endocrinol. (Oxf) 2008, 68:102-107.
29. Dallinga-Thie G.M., Bu X.D., van Linde-Sibenius Trip M., Rotter J.I., Lusis A.J., de Bruin T.W. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J. Lipid Res. 1996, 37:136-147.
30. Mooradian A., Haas M., Wong N. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 2004, 53:513-520.
31. Mogilenko D.A., Dizhe E.B., Shavva V.S., Lapikov I.A., Orlov S.V., Perevozchikov A.P. Role of the nuclear receptors HNF4alpha, PPARalpha, and LXRs in the TNFalpha-mediated inhibition of human apolipoprotein A-I gene expression in HepG2 cells. Biochemistry 2009, 48:11950-11960.
32. Ito Y., Azrolan N., O'Connell A., Walsh A., Breslow J.L. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990, 249:790-793.
33. Maeda N., Li H., Lee D., Oliver P., Quarfordt S.H., Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 1994, 269:23610-23616.
34. Waterworth D.M., Ribalta J., Nicaud V., Dallongeville J., Humphries S.E., Talmud P. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 1999, 99:1872-1877.
35. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J. Intern. Med. 1999, 246:341-355.
36. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007, 298:309-316.
37. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007, 298:299-308.
38. Attia N., Durlach V., Cambilleau M., Roche D., Girard-Globa A. Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment. Atherosclerosis 2000, 149:427-433.
39. Delgado-Lista J., Perez-Jimenez F., Ruano J., Perez-Martinez P., Fuentes F., Criado-Garcia J., Parnell L.D., Garcia-Rios A., Ordovas Test J.M. Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men. J. Lipid Res. 2010, 51:63-73.
40. Esterbauer H., Hell E., Krempler F., Patsch W. Allele-specific differences in apolipoprotein C-III mRNA expression in human liver. Clin. Chem. 1999, 45:331-339.
41. Russo G.T., Meigs J.B., Cupples L.A., Demissie S., Otvos J.D., Wilson P.W., Lahoz C., Cucinotta D., Couture P., Mallory T., Schaefer E.J., Ordovas J.M. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis 2001, 58:173-181.
42. Stancáková A., Baldaufová L., Javorskỳ M., Kozárová M., Salagovic J., Tkác I. Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome. Physio.l Res. 2006, 55:483-490.